MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin
暂无分享,去创建一个
Aiju Fang | L. Du | Yong-mei Yang | Xin Zhang | Chuanxin Wang | Tong Liu | Peilong Li | Chuanxin Wang | Lutao Du | Xin Zhang | Yongmei Yang | Tong Liu | Zewu Li | Yanli Zhang | Xinfeng Liu | Aiju Fang | Peilong Li | Zewu Li | Xin-Fu Liu | Yan-li Zhang | Lutao Du
[1] Min Liu,et al. MiR‐214 reduces cell survival and enhances cisplatin‐induced cytotoxicity via down‐regulation of Bcl2l2 in cervical cancer cells , 2013, FEBS letters.
[2] W. Youden,et al. Index for rating diagnostic tests , 1950, Cancer.
[3] M. Bushell,et al. microRNAs in cancer management. , 2012, The Lancet. Oncology.
[4] L. Du,et al. MiR-203 Suppresses ZNF217 Upregulation in Colorectal Cancer and Its Oncogenicity , 2015, PloS one.
[5] A. Caudy,et al. Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .
[6] D. Grignon,et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. , 2013, European urology.
[7] F. Montorsi,et al. Survivin as a Prognostic Marker for Urothelial Carcinoma of the Bladder: A Multicenter External Validation Study , 2009, Clinical Cancer Research.
[8] John Calvin Reed,et al. An IAP-IAP Complex Inhibits Apoptosis* , 2004, Journal of Biological Chemistry.
[9] Gang-yi Yang,et al. MicroRNA‐203 down‐regulation is associated with unfavorable prognosis in human glioma , 2013, Journal of surgical oncology.
[10] Naser Asl Aminabadi,et al. MicroRNAs as prognostic molecular signatures in human head and neck squamous cell carcinoma: a systematic review and meta-analysis. , 2015, Oral oncology.
[11] R. deVere White,et al. MiR‐34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53‐Rb pathway status , 2012, International journal of cancer.
[12] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[13] D. Bajorin,et al. Defining optimal therapy for muscle invasive bladder cancer. , 2007, The Journal of urology.
[14] G. Sonpavde,et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. , 2013, European urology.
[15] Andrea Ventura,et al. MicroRNAs and Cancer: Short RNAs Go a Long Way , 2009, Cell.
[16] M. Moore,et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] R. Dahiya,et al. Curcumin Modulates MicroRNA-203–Mediated Regulation of the Src-Akt Axis in Bladder Cancer , 2011, Cancer Prevention Research.
[18] Y. Xiong,et al. A Bmi1-miRNAs Cross-Talk Modulates Chemotherapy Response to 5-Fluorouracil in Breast Cancer Cells , 2013, PloS one.
[19] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[20] Yuquan Wei,et al. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. , 2012, Journal of biomedical nanotechnology.
[21] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Hartmann,et al. Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11 , 2014, Clinical Cancer Research.
[23] Yangde Zhang,et al. miR-203 reverses chemoresistance in p53-mutated colon cancer cells through downregulation of Akt2 expression. , 2011, Cancer letters.
[24] Kefeng Wang,et al. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1 , 2014, Cancer Cell International.
[25] T. Ørntoft,et al. miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer , 2012, BMC Medical Genomics.
[26] L. Ellis,et al. miR‐203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase , 2014, Molecular oncology.
[27] G. Tsongalis,et al. MicroRNAs: novel biomarkers for human cancer. , 2009, Clinical chemistry.
[28] Kenneth K Wang,et al. MicroRNA Expression Signatures during Malignant Progression from Barrett's Esophagus to Esophageal Adenocarcinoma , 2013, Cancer Prevention Research.
[29] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[30] A. Yadav,et al. YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels , 2012, Molecular Cancer Therapeutics.
[31] Qunshu Zhang,et al. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells , 2010, Cell Death and Disease.
[32] L. Galluzzi,et al. Molecular mechanisms of cisplatin resistance , 2012, Oncogene.
[33] X. Wang. The expanding role of mitochondria in apoptosis. , 2001, Genes & development.
[34] Pan Xu,et al. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells , 2015, PloS one.
[35] S. Groshen,et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[37] Lan Liu,et al. Overexpression of miR-214-3p in Esophageal Squamous Cancer Cells Enhances Sensitivity to Cisplatin by Targeting Survivin Directly and Indirectly Through CUG-BP1 , 2015, Oncogene.